IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimer’s disease. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aβ plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aβ plaques and neurofibrillary tangles for a comprehensive therapeutic effect. It seeks to leverage artificial intelligence (AI) for Alzheimer's research.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 869.00K.
Sobreavaliada
O PE mais recente da empresa é 43.12, em uma faixa percentil alta de 3 anos.
Compra Institucional
As participações institucionais mais recentes são de 22.48M ações, um aumento de 11.30% em relação ao trimestre anterior.
Mantido por Ken Fisher
O Super Investidor Ken Fisher possui 39.34K ações desta empresa.
Baixa Atividade de Mercado
A empresa tem menor interesse dos investidores, com uma taxa de giro de 20 dias de -0.28.